Suppr超能文献

评估尿中羟基吡啶交联测量作为代谢性骨病中再吸收标志物的情况。

Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases.

作者信息

Robins S P, Black D, Paterson C R, Reid D M, Duncan A, Seibel M J

机构信息

Biochemical Sciences Division, Rowett Research Institute, Bucksburn, Aberdeen, Scotland.

出版信息

Eur J Clin Invest. 1991 Jun;21(3):310-5. doi: 10.1111/j.1365-2362.1991.tb01375.x.

Abstract

Analyses of the urinary concentration relative to creatinine of the collagen crosslinks, pyridinoline (Pyd) and deoxy-pyridinoline (Dpd) were made in 47 patients with metabolic bone diseases to assess the validity of these assays as indicators of bone resorption. The mean values for patients with Paget's disease of bone, primary hyperparathyroidism and osteomalacia were significantly higher (P less than 0.001) than those for age-matched healthy individuals. During treatment of Paget's disease with bisphosphonates, there was a steady decline in the urinary concentration of the crosslinks to the normal range; this change occurred earlier than for serum alkaline phosphatase. There were significant correlations (P less than 0.01) between the concentrations of both crosslinks and the corresponding values for hydroxyproline. At lower crosslink concentrations, however, these relationships were less marked due to large variations in hydroxyproline values. The results show that measurements of urinary Pyd and Dpd provide clinically applicable indices of bone resorption that are more specific than other markers.

摘要

对47例代谢性骨病患者的尿中胶原交联物吡啶啉(Pyd)和脱氧吡啶啉(Dpd)相对于肌酐的浓度进行了分析,以评估这些检测作为骨吸收指标的有效性。患有骨Paget病、原发性甲状旁腺功能亢进和骨软化症患者的平均值显著高于(P<0.001)年龄匹配的健康个体。在用双膦酸盐治疗骨Paget病期间,交联物的尿浓度稳步下降至正常范围;这种变化比血清碱性磷酸酶出现得更早。两种交联物的浓度与羟脯氨酸的相应值之间存在显著相关性(P<0.01)。然而,在较低的交联物浓度下,由于羟脯氨酸值的较大变化,这些关系不太明显。结果表明,尿Pyd和Dpd的测量提供了临床上适用的骨吸收指标,比其他标志物更具特异性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验